Westport-based Intensity Therapeutics has presented preclinical results from a study of the company’s lead product, INT230-6. The results show significantly increased antitumor response using a combination of INT230-6 with an anti-PD-1 antibody compared to combined administration of anti-PD-1 and anti-CTLA-4 antibodies.